NAS:ASRT (USA) Also trade in: Germany

Assertio Therapeutics Inc

$ 3.4 -0.03 (-0.87%)
Volume: 564,702 Avg Vol (1m): 930,937
Market Cap $: 218.98 Mil Enterprise Value $: 653.31 Mil
P/E (TTM): 0.00 P/B: 1.05
Earnings Power Value 8.73
Net Current Asset Value -7.67
Tangible Book -7.13
Projected FCF 10.95
Median P/S Value 10.38
Graham Number 0
Peter Lynch Value -1.62
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 4/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 0.20
Cash-To-Debt ranked lower than
91.04% of 859 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 91151, Med: 2.03, Min: -0.01
ASRT: 0.2
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.1, Med: 9.14, Max: 10000
Current: 0.2
0.1
10000
Equity-to-Asset 0.24
Equity-to-Asset ranked lower than
91.62% of 788 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1.78, Med: 0.64, Min: -27.83
ASRT: 0.24
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: -2.63, Med: 0.27, Max: 0.97
Current: 0.24
-2.63
0.97
Debt-to-Equity 2.61
Debt-to-Equity ranked lower than
97.32% of 596 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 31.22, Med: 0.32, Min: 0.01
ASRT: 2.61
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: -8.32, Med: 0.41, Max: 5.13
Current: 2.61
-8.32
5.13
Debt-to-EBITDA 3.33
Debt-to-EBITDA ranked lower than
74.34% of 495 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 343059.67, Med: 1.92, Min: 0.01
ASRT: 3.33
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -0.29, Med: 2.65, Max: 22.27
Current: 3.33
-0.29
22.27
Interest Coverage 0.10
Interest Coverage ranked lower than
97.69% of 648 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 2689668, Med: 86.08, Min: 0.01
ASRT: 0.1
Ranked among companies with meaningful Interest Coverage only.
Interest Coverage range over the past 10 years
Min: 0.1, Med: 4.04, Max: 230.81
Current: 0.1
0.1
230.81
Piotroski F-Score 7
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0.32
DISTRESS
GREY
SAFE
Beneish M-Score -3.74
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 1.17%
WACC 11.85%

Profitability & Growth : 7/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % 2.89
Operating Margin ranked higher than
57.80% of 801 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 8950, Med: 7.97, Min: -232970.37
ASRT: 2.89
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -38.23, Med: 4.94, Max: 60.67
Current: 2.89
-38.23
60.67
Net Margin % -4.65
Net Margin ranked lower than
73.32% of 802 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 304900, Med: 5.32, Min: -216285.19
ASRT: -4.65
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -38.12, Med: -7.32, Max: 53.19
Current: -4.65
-38.12
53.19
ROE % -5.25
ROE ranked lower than
74.76% of 832 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 316.96, Med: 5.94, Min: -3119.47
ASRT: -5.25
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -90.05, Med: -1.68, Max: 109.63
Current: -5.25
-90.05
109.63
ROA % -1.19
ROA ranked lower than
67.28% of 871 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 943.36, Med: 2.88, Min: -1851.14
ASRT: -1.19
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -23.58, Med: -1.57, Max: 56.27
Current: -1.19
-23.58
56.27
ROC (Joel Greenblatt) % 449.31
ROC (Joel Greenblatt) ranked higher than
98.01% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 34233.33, Med: 11.23, Min: -2671900
ASRT: 449.31
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -2282.52, Med: 123.58, Max: 8060.52
Current: 449.31
-2282.52
8060.52
3-Year Total Revenue Growth Rate -3.10
3-Year Revenue Growth Rate ranked lower than
67.63% of 689 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 291.9, Med: 5.8, Min: -100
ASRT: -5.2
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: -74.4, Med: 25.5, Max: 517.8
Current: -5.2
-74.4
517.8
3-Year Total EBITDA Growth Rate 81.10
3-Year EBITDA Growth Rate ranked lower than
91.90% of 704 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 299.6, Med: 7.3, Min: -343.2
ASRT: 77.1
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: 0, Med: -6.7, Max: 95.7
Current: 77.1
0
95.7

» ASRT's 30-Y Financials

Financials (Next Earnings Date: 2019-08-08)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:ASRT

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS : 325412    SIC : 2834
Compare XCNQ:PLTH TSXV:HIP NYSE:LCI BOM:532612 TSXV:ZENA XCNQ:MMEN XKRX:002250 XCNQ:IAN OSTO:ORX SZSE:002817 XCNQ:HUGE XKRX:102460 XKRX:008490 XCNQ:TER ROCO:6576 SZSE:300534 XKRX:191420 TSE:4517 XKRX:222040 XCNQ:VGW
Traded in other countries DPOA.Germany
Address 100 S. Saunders Road, Suite 300, Lake Forest, IL, USA, 60045
Depomed is a specialty and generic drug manufacturer. The company is focused on pain and central nervous system conditions. Depomed operates solely in the United States. It also has recognized license and royalty revenue from license agreements in the territories of the U.S., Canada, and Korea. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Ratios

Current vs industry vs history
Forward PE Ratio 4.08
Forward P/E ranked higher than
90.99% of 111 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 322.58, Med: 21.6, Min: 5.03
ASRT: 4.08
Ranked among companies with meaningful Forward P/E only.
N/A
Price-to-Owner-Earnings 2.55
Price-to-Owner-Earnings ranked lower than
100.00% of 324 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 3160, Med: 31.95, Min: 0.17
ASRT: 2.55
Ranked among companies with meaningful Price-to-Owner-Earnings only.
Price-to-Owner-Earnings range over the past 10 years
Min: 2.5, Med: 8.04, Max: 212
Current: 2.55
2.5
212
PB Ratio 1.05
PB Ratio ranked higher than
54.70% of 819 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 227.39, Med: 2.64, Min: 0.05
ASRT: 1.05
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 1.02, Med: 3.81, Max: 22.64
Current: 1.05
1.02
22.64
PS Ratio 0.97
PS Ratio ranked higher than
78.32% of 775 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 9105.26, Med: 3.1, Min: 0.03
ASRT: 0.97
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 0.74, Med: 2.97, Max: 6.55
Current: 0.97
0.74
6.55
Price-to-Free-Cash-Flow 2.05
Price-to-Free-Cash-Flow ranked higher than
51.01% of 298 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 3143.75, Med: 30.84, Min: 0.23
ASRT: 2.05
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
Price-to-Free-Cash-Flow range over the past 10 years
Min: 2.01, Med: 8.27, Max: 291.05
Current: 2.05
2.01
291.05
Price-to-Operating-Cash-Flow 1.97
Price-to-Operating-Cash-Flow ranked lower than
65.31% of 392 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 14229.87, Med: 22, Min: 0.23
ASRT: 1.97
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 1.93, Med: 8.15, Max: 271.08
Current: 1.97
1.93
271.08
EV-to-EBIT 11.31
EV-to-EBIT ranked lower than
80.94% of 572 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1015380.11, Med: 17.85, Min: 0.13
ASRT: 11.31
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -302.2, Med: 2.1, Max: 309.7
Current: 11.31
-302.2
309.7
EV-to-EBITDA 4.01
EV-to-EBITDA ranked higher than
85.93% of 597 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 341528.02, Med: 15.24, Min: 0.12
ASRT: 4.01
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -582.9, Med: 4.4, Max: 124.5
Current: 4.01
-582.9
124.5
EV-to-Revenue 2.69
EV-to-Revenue ranked higher than
59.25% of 795 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 23858.8, Med: 3.24, Min: 0.03
ASRT: 2.69
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 0.2, Med: 2.6, Max: 7.1
Current: 2.69
0.2
7.1
Current Ratio 0.82
Current Ratio ranked lower than
96.14% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 413.44, Med: 2.39, Min: 0.02
ASRT: 0.82
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.55, Med: 2.64, Max: 56
Current: 0.82
0.55
56
Quick Ratio 0.80
Quick Ratio ranked lower than
93.68% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 413.44, Med: 1.87, Min: 0.02
ASRT: 0.8
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.53, Med: 2.61, Max: 56
Current: 0.8
0.53
56
Days Inventory 170.79
Days Inventory ranked higher than
78.41% of 755 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 950.68, Med: 119.8, Min: 0.2
ASRT: 170.79
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 49.12, Med: 175.16, Max: 507.84
Current: 170.79
49.12
507.84
Days Sales Outstanding 65.78
Days Sales Outstanding ranked higher than
83.25% of 770 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 864.61, Med: 81.76, Min: 0.1
ASRT: 65.78
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 26.25, Med: 49.3, Max: 82.13
Current: 65.78
26.25
82.13
Days Payable 219.68
Days Payable ranked lower than
90.11% of 758 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 952.38, Med: 76.32, Min: 0.04
ASRT: 219.68
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 50.32, Med: 94.48, Max: 219.68
Current: 219.68
50.32
219.68

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -1.70
3-Year Share Buyback Rate ranked higher than
65.32% of 571 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 100, Med: -5.3, Min: -815
ASRT: -1.7
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -58.9, Med: -7.1, Max: -1.7
Current: -1.7
-58.9
-1.7

Valuation & Return

Current vs industry vs history
Price-to-Projected-FCF 0.31
Price-to-Intrinsic-Value-Projected-FCF ranked higher than
93.58% of 374 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 209, Med: 2.11, Min: 0.05
ASRT: 0.31
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 0.3, Med: 2.01, Max: 335
Current: 0.31
0.3
335
Price-to-Median-PS-Value 0.33
Price-to-Median-PS-Value ranked higher than
88.43% of 743 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 238.36, Med: 0.94, Min: 0.01
ASRT: 0.33
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.29, Med: 1.54, Max: 394
Current: 0.33
0.29
394
Earnings Yield (Joel Greenblatt) % 8.84
Earnings Yield (Greenblatt) ranked lower than
53.29% of 867 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 769.23, Med: 3.31, Min: -333.33
ASRT: 8.84
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -202.8, Med: 0.5, Max: 251.9
Current: 8.84
-202.8
251.9
Forward Rate of Return (Yacktman) % 33.37
Forward Rate of Return ranked lower than
100.00% of 421 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 559.55, Med: 8.96, Min: -1635.32
ASRT: 33.37
Ranked among companies with meaningful Forward Rate of Return only.
Forward Rate of Return range over the past 10 years
Min: -8.6, Med: 1.4, Max: 39
Current: 33.37
-8.6
39

More Statistics

Revenue (TTM) (Mil) $ 241.3
EPS (TTM) $ -0.28
Beta 1.82
Volatility % 69.65
52-Week Range $ 3.09 - 9.48
Shares Outstanding (Mil) 64.41

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 7
Positive ROA N
Positive CFROA Y
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy Y
Higher Gross Margin yoy Y
Higher Asset Turnover yoy N